Compare · head to head
Chong Kun Dang vs GC Biopharma
Chong Kun Dang ranks higher overall — 360 rank 55 vs 52.
GC Biopharma leads on Value (62 vs 52), Quality (67 vs 44) and Growth (50 vs 40). Chong Kun Dang leads on Safety (55 vs 25) and Sentiment (64 vs 47).
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | South Korea | South Korea |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals | Biotechnology |
| Size | Small | Small |
| ISIN | KR7185750007 | KR7006280002 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 55 | 52 |
| Value | 52 | 62 |
| Quality | 44 | 67 |
| Growth | 40 | 50 |
| Safety | 55 | 25 |
| Sentiment | 64 | 47 |
| Quality details | ||
| Profitability | 55 | 76 |
| Cash Truth | 33 | 58 |
Chong Kun Dang vs YuhanChong Kun Dang vs Sumitomo Dainippon PharmaChong Kun Dang vs Dongwha PharmChong Kun Dang vs Lotus PharmaceuticalAdd a third stock →
Full analyses: Chong Kun Dang · GC Biopharma
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100